Cinacalcet use in paediatric dialysis: a position statement from the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders Working Group of the ERA-EDTA
Authors:
- Justine BacchettaJBJustine Bacchetta
- Mandy WanMWMandy Wan
- Marc VervloetMVMarc Vervloet
- Rukshana ShroffRSRukshana Shroff
- on behalf of the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders and Dialysis Working Group of the ERA-EDTAOEon behalf of the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders and Dialysis Working Group of the ERA-EDTA
- 22 October 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 35 (1) , 47-64
Abstract
Secondary hyperparathyroidism (SHPT) is an important complication of advanced chronic kidney disease (CKD) in children, which is often difficult to treat with conventional therapy. The calcimimetic cinacalcet is an allosteric modulator of the calcium-sensing receptor. It has proven to be effective and safe in adults to suppress parathyroid hormone (PTH), but data on its use in children are limited. To date, studies in children only consist of two randomized controlled trials, nine uncontrolled interventional or observational studies, and case reports that report the efficacy of cinacalcet as a PTH-lowering compound. In 2017, the European Medical Agency approved the use of cinacalcet for the treatment of SHPT in children on dialysis in whom SHPT is not adequately controlled with standard therapy. Since evidence-based guidelines are so far lacking, we present a position statement on the use of cinacalcet in paediatric dialysis patients based on the available evidence and opinion of experts from the European Society for Paediatric Nephrology, Chronic Kidney Disease-Mineral and Bone Disorder and Dialysis Working Groups, and the ERA-EDTA. Given the limited available evidence the strength of these statements are weak to moderate, and must be carefully considered by the treating physician and adapted to individual patient needs as appropriate. Audit and research recommendations to study key outcome measures in paediatric dialysis patients receiving cinacalcet are suggested.Keywords
Funding Information
- ESPN
This publication has 52 references indexed in Scilit:
- Short- and middle-term continuous use of cinacalcet in children on peritoneal dialysisJournal of Pediatric Endocrinology and Metabolism, 2013
- Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing DialysisNew England Journal of Medicine, 2012
- Searching the optimal PTH target range in children undergoing peritoneal dialysis: New insights from international cohort studiesPediatric Nephrology, 2012
- An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjectsPediatric Nephrology, 2012
- Early Skeletal and Biochemical Alterations in Pediatric Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2012
- Cardiac Geometry in Children Receiving Chronic Peritoneal DialysisClinical Journal of the American Society of Nephrology, 2011
- Value of the New Bone Classification System in Pediatric Renal OsteodystrophyClinical Journal of the American Society of Nephrology, 2010
- Middle-term use of Cinacalcet in paediatric dialysis patientsPediatric Nephrology, 2010
- Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patientsKidney International, 2006
- Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trialsPediatric Nephrology, 2003